DCTD Programs
Last Updated: 10/25/2019
DCTD-supported Research Presentations at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Below is a list of DCTD-supported research presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 
(October 26-30, 2019; Boston, MA). The European Organisation for Research and Treatment of Cancer (EORTC), NCI, and the American Association for Cancer Research (AACR) co-host the meeting. DCTD’s Director, James H. Doroshow, MD, is an Organizing Committee Co-Chair. All abstracts can be viewed on the conference website
.
| Abstract Title | Authors |
|---|---|
| Sunday, October 27 | |
| A-050 — Validation of beta-catenin as a tumor segmentation marker for delineating tumor from stromal tissues in quantitative multiplex immunofluorescence analysis of formalin-fixed, paraffin-embedded biopsies | T Navas, R Kinders, H Makhlouf, S Lawrence, R Chuaqui, K Fino, A Dull, K Ferry-Galow, D Wilsker, A Chen, S Kumar, R Parchment, J Doroshow |
| A-71 — Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes | S Khan, G O’Sullivan-Coyne, L Rubinstein, Si Kummar, L Juwara, J Zlott, A Mittra, M Hogu, J Collins, A Srivastava, B Miller, R Parchment, C Hourigan, S Pavletic, J Doroshow, A Chen, N Takebe |
| A-079 — National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies | L Harris, R Gray, B Conley, A Chen, K Flaherty, S Hamilton, P Williams, C Karlovich, D Patton, S Li, L McShane, L Rubinstein, E Mitchell, J Tricoli, R Little, C Arteaga, P O’Dwyer |
| A-089 — Adolescent and young adult (AYA) cohort of the NCI-MATCH clinical trial (EAY131) | A Chen, S Li, B Coffey, J Tricoli, S Hamilton, M Williams, E Mitchell, D Patton, R Gray, L McShane, L Rubinstein, C Arteaga, P O’Dwyer, L Harris, B Conley, K Flaherty |
| Monday, October 28 | |
| B-013 — Associations of epigenome-wide DNA methylation patterns with chemosensitivity and chemoresistance of small cell lung cancer cell lines | J Krushkal, T Silvers, D Sonkin, S Vural, J Connelly, S Varma, P. Meltzer, W Reinhold, A Rapisarda, D Evans, Y Pommier, B Teicher |
| B-018 — Restoration of p16INK4A expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes | L Wang, B Miller, S Khin, G O’Sullivan-Coyne, A Chen, S Kummar, N Takebe, K Ferry-Galow, R Parchment, L Rubinstein, R Piekarz, E Newman, J Doroshow, R Kinders |
| B-105 — Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas | G O’Sullivan Coyne, T Yap, N Moore, A Mittra, N Takebe, L Juwara, S Khan, E Dumbrava, H Streicher, R Piekarz, E Sharon, F Meric-Bernstam, R Parchment, T Navas, K Fung, J Mitchell, K Fino, S Montez, A Doyle, L Rubinstein, J Doroshow, A Chen |
| Tuesday, October 29 | |
| Late-Breaking — Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN) | G O'Sullivan Coyne, A Gross, E Dombi, J DeSanto, A Carbonell, J Derdak, D Pichard, B Wood, C Tibery, P Wolters, T Whitcomb, S Martin, D Bradford, A Srivastava, W Herrick, R Parchment, K Helsey, A Doyle, N Takebe, JH Doroshow, B Widemann |
| C-008 — Tolerability and antitumor activity of paclitaxel is improved by the addition of nilotinib in patients with refractory solid tumors | G O’Sullivan Coyne, S Kummar, J Zlott, L Juwara, N Takebe, M Hogu, L Anderson, J Collins, R Piekarz, H Streicher, E Sharon, A Mittra, S Khan, B Miller, T Navas, A Srivastava, R Parchment, L Rubinstein, J Doroshow, A Chen |